About MaxCyte Inc
Ticker
info
MXCT
Trading on
info
NASDAQ
ISIN
info
US57777K1060
Industry
info
Medical Devices
Sector
info
Healthcare
CEO
info
Maher Masoud
Headquarters
info
9713 Key West Avenue, Rockville, MD, United States, 20850
Employees
info
114
Website
info
maxcyte.com
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Metrics
BasicAdvanced
Market cap
info
$162M
P/E ratio
info
-
EPS
info
-$0.43
Dividend Yield
info
0.00%
Beta
info
0.33
Forward P/E ratio
info
0
EBIDTA
info
$-46.2M
Ex dividend date
info
-
Price & volume
Market cap
info
$162M
Average daily volume
info
1.4M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
4.71
Price to book
info
0.9
Earnings
EPS
info
-$0.43
EPS estimate (current quarter)
info
-$0.10
EPS estimate (next quarter)
info
-$0.09
EBITDA
info
$-46.2M
Revenues (TTM)
info
$34.4M
Revenues per share (TTM)
info
$0.32
Technicals
Beta
info
0.33
52-week High
info
$5.20
52-week Low
info
$1.26
50-day moving average
info
$1.62
200-day moving average
info
$2.17
Short ratio
info
4.74
Short %
info
2.84%
Management effectiveness
ROE (TTM)
info
-23.19%
ROA (TTM)
info
-13.67%
Profit margin
info
-132.58%
Gross profit margin
info
$27.5M
Operating margin
info
-162.41%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
-16.40%
Share stats
Outstanding Shares
info
107M
Float
info
96.9M
Insiders %
info
1.77%
Institutions %
info
75.51%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 6 analysts.

Average price target

info
$6.68
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.10
-$0.12
16.67%
Q4 • 24Beat
-$0.10
-$0.13
23.08%
Q1 • 25Beat
-$0.12
-$0.10
-20.00%
Q2 • 25Missed
-$0.12
-$0.11
-5.91%
Q3 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$8.5M
$-12.4M
-145.26%
Q2 • 25
$6.8M
$-12.4M
-181.81%
Q3 • 25
-19.72%
0.48%
25.17%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$220M
$29M
13.21%
Q2 • 25
$213M
$33.2M
15.55%
Q3 • 25
-2.86%
14.38%
17.74%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-9.9M
$1.5M
$0.2M
$-10.4M
Q2 • 25
$-7.5M
$5.2M
$0M
$-7.8M
Q3 • 25
-24.30%
237.58%
-90.91%
-25.66%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a MaxCyte Inc share?
Collapse

MaxCyte Inc shares are currently traded for undefined per share.

How many shares does MaxCyte Inc have?
Collapse

MaxCyte Inc currently has 107M shares.

Does MaxCyte Inc pay dividends?
Collapse

No, MaxCyte Inc doesn't pay dividends.

What is MaxCyte Inc 52 week high?
Collapse

MaxCyte Inc 52 week high is $5.20.

What is MaxCyte Inc 52 week low?
Collapse

MaxCyte Inc 52 week low is $1.26.

What is the 200-day moving average of MaxCyte Inc?
Collapse

MaxCyte Inc 200-day moving average is $2.17.

Who is MaxCyte Inc CEO?
Collapse

The CEO of MaxCyte Inc is Maher Masoud.

How many employees MaxCyte Inc has?
Collapse

MaxCyte Inc has 114 employees.

What is the market cap of MaxCyte Inc?
Collapse

The market cap of MaxCyte Inc is $162M.

What is the P/E of MaxCyte Inc?
Collapse

The current P/E of MaxCyte Inc is null.

What is the EPS of MaxCyte Inc?
Collapse

The EPS of MaxCyte Inc is -$0.43.

What is the PEG Ratio of MaxCyte Inc?
Collapse

The PEG Ratio of MaxCyte Inc is null.

What do analysts say about MaxCyte Inc?
Collapse

According to the analysts MaxCyte Inc is considered a buy.